TIZIMLI SKLERODERMIYADA O‘PKA ZARARLANISHINING KLINIK-IMMUNOLOGIK JIHATLARI
Keywords:
tizimli sklerodermiya,, anti-fibrillarin antitanalari,, bazal pnevmofibroz,, o‘pka tiriklik sig‘imi,, forsirlangan o‘pka tiriklik sig‘imiAbstract
Tizimli sklerodermiya (TSD) — surunkali, progressiv kechuvchi autoimmun kasallik bo‘lib, biriktiruvchi to‘qimalarda fibroz jarayonlar, kichik tomirlar endoteliyasining zararlanishi va keng qamrovli immun buzilishlar bilan tavsiflanadi. Kasallikning tarqalishi umumiy populyatsiyada 100 ming aholiga 7–25 ta holatni tashkil etadi. Ayniqsa, interstitsial o‘pka kasalligi va o‘pka gipertenziyasi kabi asoratlar bemorlarning erta nogironlikka chiqishiga va yuqori o‘lim ko‘rsatkichlariga olib keluvchi yetakchi omillardan biridir. Ushbu kasallikning ijtimoiy va iqtisodiy ahamiyati ham katta bo‘lib, nogironlikning erta rivojlanishi, uzoq muddatli davolanish zarurati hamda sog‘liqni saqlash tizimiga tushadigan katta moliyaviy yuk tufayli dolzarb muammo sifatida ko‘riladi. Shuning uchun tizimli sklerodermiyada o‘pka zararlanishining klinik va immunologik xususiyatlarini o‘rganish, erta tashxis va samarali davolash usullarini ishlab chiqish muhim ilmiy-amaliy ahamiyatga ega.
References
1. Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020 Mar;8(3):304-320. doi: 10.1016/S2213-2600(19)30480-1. Epub 2020 Feb 27. PMID: 32113575.
2. Jerjen R, Nikpour M, Krieg T, Denton CP, Saracino AM. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. J Am Acad Dermatol. 2022 Nov;87(5):937-954. doi: 10.1016/j.jaad.2021.10.065. Epub 2022 Feb 4. PMID: 35131402.
3. Liakouli V, Ciancio A, Del Galdo F, Giacomelli R, Ciccia F. Systemic sclerosis interstitial lung disease: unmet needs and potential solutions. Nat Rev Rheumatol. 2024 Jan;20(1):21-32. doi: 10.1038/s41584-023-01044-x. Epub 2023 Nov 3. PMID: 37923862.
4. Scallan CJ, Collins BF, Raghu G. Systemic sclerosis-associated interstitial lung disease. Curr Opin Pulm Med. 2020 Sep;26(5):487-495. doi: 10.1097/MCP.0000000000000707. PMID: 32740379.
5. Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. Am J Respir Crit Care Med. 2020 Mar 15;201(6):650-660. doi: 10.1164/rccm.201903-0563CI. PMID: 31841044; PMCID: PMC7068837.
6. Papazoglou A, Huang M, Bulik M, Lafyatis A, Tabib T, Morse C, Sembrat J, Rojas M, Valenzi E, Lafyatis R. Epigenetic Regulation of Profibrotic Macrophages in Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2022 Dec;74(12):2003-2014. doi: 10.1002/art.42286. Epub 2022 Oct 31. PMID: 35849803; PMCID: PMC9771864.
